Skip to Main Content

Author Details

Francis J Hornicek
Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami
1983
408
66
PMIDPaper TitleJournal TitlePublished Year
36804377Transcriptional Profiling Supports the Notochordal Origin of Chordoma and Its Dependence on a TGFB1-TBXT Network.Am J Pathol2023
37892917Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients.Bioengineering (Basel)2023
37768856Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1) Is a Novel Therapeutic Target in Liposarcoma: A Tissue Microarray Study.Clin Orthop Relat Res2023
37970365Erratum: ATR inhibition sensitizes liposarcoma to doxorubicin by increasing DNA damage.Am J Cancer Res2023
37292676The landscape of drug sensitivity and resistance in sarcoma.bioRxiv2023
37408255Therapeutic Perspectives for Inflammation and Senescence in Osteoarthritis Using Mesenchymal Stem Cells, Mesenchymal Stem Cell-Derived Extracellular Vesicles and Senolytic Agents.Cells2023
36622936Analysis of Questions in Sections of the Orthopaedic In-Training Examination: A Scoping Review.J Am Acad Orthop Surg2023
35171675Personalized chordoma organoids for drug discovery studies.Sci Adv2022
35809223Pedicled vastus lateralis myocutaneous flap for sacropelvic defects after wide oncologic resection: Wound complications and outcomes.J Surg Oncol2022
35429502Definitive high-dose, proton-based radiation for unresected mobile spine and sacral chordomas.Radiother Oncol2022
35367753Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma.Biomed Pharmacother2022
35530299ATR inhibition sensitizes liposarcoma to doxorubicin by increasing DNA damage.Am J Cancer Res2022
35388973Expression and Clinical Significance of High-Mobility Group AT-hook 2 (HMGA2) in Osteosarcoma.Orthop Surg2022
36043432In situ hybridization to detect DNA amplification in extracellular vesicles.J Extracell Vesicles2022
35995141Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential.Cancer Lett2022
36064358Exosomes in the tumor microenvironment of sarcoma: from biological functions to clinical applications.J Nanobiotechnology2022
36195275Advances in the development of chordoma models for drug discovery and precision medicine.Biochim Biophys Acta Rev Cancer2022
34984436SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma.Biosci Rep2022
34115928T-LAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma.Mol Oncol2021
33582212Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation.Cancer Lett2021
33798728Updated external validation of the SORG machine learning algorithms for prediction of ninety-day and one-year mortality after surgery for spinal metastasis.Spine J2021
34484648Aggressive osteoblastoma with a secondary aneurysmal bone cyst treated with denosumab.Rare Tumors2021
34767468Establishment and Characterization of a Novel Dedifferentiated Chondrosarcoma Cell Line DDCS2.Cancer Control2021
34104229Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma.Ther Adv Musculoskelet Dis2021
34040980Distal femoral replacement - Cemented or cementless? Current concepts and review of the literature.J Clin Orthop Trauma2021
33932923Feasibility of achieving planned surgical margins in primary spine tumor: a PTRON study.Neurosurg Focus2021
29889796Henry J. Mankin: A Trailblazer in Skeletal Pathology Research.Spine (Phila Pa 1976)2020
33854565ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer.Ther Adv Med Oncol2020
31758570Association between patient age and the risk of mortality following local recurrence of a sacral chordoma.J Surg Oncol2020
32087389Surgical treatment of metastatic spine disease: an update on national trends and clinical outcomes from 2010 to 2014.Spine J2020
31806415The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma.Eur J Cancer2020
31634526Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application.Cancer Lett2020
31987920Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy.Cancer Lett2020
31892980Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.J Cancer2020
31794912Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications.Cancer Treat Rev2020
31736134Establishment and Characterization of a Recurrent Osteosarcoma Cell Line: OSA 1777.J Orthop Res2020
33282745Prognostic Significance of Cyclin E1 Expression in Patients With Chordoma: A Clinicopathological and Immunohistochemical Study.Front Oncol2020
33157532The use of autologous free vascularized fibula grafts in reconstruction of the mobile spine following tumor resection: surgical technique and outcomes.J Neurosurg Spine2020
32691223Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value.Eur Spine J2020
32887645The role of extracelluar matrix in osteosarcoma progression and metastasis.J Exp Clin Cancer Res2020
32827577PTEN in osteosarcoma: Recent advances and the therapeutic potential.Biochim Biophys Acta Rev Cancer2020
32960500T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma.Cell Prolif2020
32902907Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma.J Orthop Res2020
32173158Corrigendum to "HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1" [Biochim. Biophys. Acta Mol. Basis Dis. 1864 (2018) 1839-1849].Biochim Biophys Acta Mol Basis Dis2020
32162720Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma.J Orthop Res2020
32426053Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma.Ther Adv Med Oncol2020
32453111Nonmechanical Revision Indications Portend Repeat Limb-Salvage Failure Following Total Femoral Replacement.J Bone Joint Surg Am2020
32157112MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma.Sci Rep2020
30664779Small-molecule targeting of brachyury transcription factor addiction in chordoma.Nat Med2019
31665012Correction to: Transcriptional activation of CBFβ by CDK11<sup>p110</sup> is necessary to promote osteosarcoma cell proliferation.Cell Commun Signal2019
  • 1 - 50 of 408

Recommended Authors

Joseph A Ludwig
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 5
Christian F Meyer
Johns Hopkins University School of Medicine
Career Start Year 2005
Number of shared co-authors 6
Sandra J Strauss
University College London, Cancer Institute
Career Start Year 2003
Number of shared co-authors 5
Bernadette Liegl-Atzwanger
Diagnostic and Research Institute of Pathology, Medical University of Graz
Career Start Year 2003
Number of shared co-authors 9
Ken Kikuchi
Kyoto Prefectural University of Medicine
Career Start Year 2002
Number of shared co-authors 0
Chantal Pauli
University Hospital Zurich
Career Start Year 2001
Number of shared co-authors 1
Sung Wook Seo
Samsung Medical Center, Sungkyunkwan University
Career Start Year 2001
Number of shared co-authors 0
Elizabeth G Demicco
Mount Sinai Hospital and Laboratory Medicine and Pathobiology, University of Toronto
Career Start Year 2000
Number of shared co-authors 7
Beate Rinner
Medical University of Graz
Career Start Year 2000
Number of shared co-authors 2
Jilong Yang
Tianjin Medical University Cancer Institute and Hospital
Career Start Year 2000
Number of shared co-authors 3
Gyeongsin Park
Seoul St. Mary's Hospital, The Catholic University of Korea
Career Start Year 1999
Number of shared co-authors 0
Angela C Hirbe
Washington University School of Medicine and Siteman Cancer Center
Career Start Year 1999
Number of shared co-authors 4
Bret Wehrli
Schulich School of Medicine & Dentistry, Western University
Career Start Year 1998
Number of shared co-authors 2
Fernanda Amary
Royal National Orthopaedic Hospital
Career Start Year 1997
Number of shared co-authors 6
Najat C Daw
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 4
Gonzague de Pinieux
University Hospital of Tours
Career Start Year 1996
Number of shared co-authors 2
Richard Gorlick
University of Texas MD Anderson Cancer Center
Career Start Year 1995
Number of shared co-authors 8
Brian P Rubin
Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic
Career Start Year 1994
Number of shared co-authors 13
Roberto Tirabosco
University College London, UCL Cancer Institute
Career Start Year 1994
Number of shared co-authors 6
Rebecca A Gladdy
Mount Sinai Hospital
Career Start Year 1994
Number of shared co-authors 9
John M Kane
Roswell Park Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 7
Jeremy Whelan
University College London Hospitals NHS Foundation Trust
Career Start Year 1991
Number of shared co-authors 5
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 1
Katia Scotlandi
IRCCS Istituto Ortopedico Rizzoli
Career Start Year 1987
Number of shared co-authors 3
Fran??oise R??dini
Nantes Universite, Inserm UMR 7, CNRS UMR 6075, Universite d'Angers
Career Start Year 1986
Number of shared co-authors 1
David M Loeb
Children's Hospital at Montefiore.
Career Start Year 1986
Number of shared co-authors 3
Ossama Tawfik
University of Kansas
Career Start Year 1985
Number of shared co-authors 0
Rex C Bentley
Duke School of Medicine
Career Start Year 1984
Number of shared co-authors 2
Lee J Helman
Osteosarcoma Institute
Career Start Year 1977
Number of shared co-authors 9
Frederick R Eilber
University of California-Los Angeles
Career Start Year 1969
Number of shared co-authors 9

Collaborators

Yen-Lin Chen
34903Fu-Jen Catholic University
Co-authored papers 40
Andrew E Rosenberg
Co-authored papers 36
Yan Gao
Co-authored papers 21
Scott D Nelson
University of California-Los Angeles
Co-authored papers 10
Yunfei Liao
Co-authored papers 9
Anthony J Iafrate
Massachusetts General Hospital
Co-authored papers 6
Nicholas M Bernthal
University of California-Los Angeles
Co-authored papers 6
Ramnik J Xavier
Broad Institute of MIT and Harvard
Co-authored papers 4
Nathanael S Gray
Harvard Medical School
Co-authored papers 4
Jay S Wunder
University of Toronto
Co-authored papers 4
Reinhard Windhager
Medical University of Vienna
Co-authored papers 4
Andrzej Niemierko
Massachusetts General Hospital
Co-authored papers 4
Carol D Morris
The Johns Hopkins Hospital
Co-authored papers 3
Jason L Hornick
Brigham and Women's Hospital and Harvard Medical School
Co-authored papers 3
Noah Federman
University of California los angeles
Co-authored papers 3
Robert L Satcher
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Arun S Singh
University of California-Los Angeles
Co-authored papers 3
David Zurakowski
Harvard Medical School, Boston Children's Hospital
Co-authored papers 3
Rakesh K Jain
Massachusetts General Hospital, Harvard Medical School
Co-authored papers 3
Raphael E Pollock
James Cancer Center, The Ohio State University
Co-authored papers 3
Alex B Haynes
Brigham and Women's Hospital, Harvard T.H. Chan School of Public Health
Co-authored papers 3
Cristina R Antonescu
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Jomjit Chantharasamee
Siriraj Hospital, Mahidol University
Co-authored papers 2
Ross Zafonte
Spaulding Rehabilitation Hospital, Harvard Medical School
Co-authored papers 2
Nasrin Tavanaie
David Geffen School of Medicine, University of California los angeles
Co-authored papers 2
Robert M Hoffman
Co-authored papers 2
John Quackenbush
Harvard T. H. Chan School of Public Health
Co-authored papers 2
Jonathan C Trent
Sylvester Comprehensive Cancer Center, University of Miami
Co-authored papers 2
Tyler Jacks
Co-authored papers 2
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 2
Release 1.2